📰 Markus Warmuth News
Markus Warmuth News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Markus Warmuth. Real-time updates on events, politics, business and more.
May 21, 2024
MRT-6160, a VAV1-directed molecular glue degrader , inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes...
May 21, 2024
#Tu1727: MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin...
May 2, 2024
02.05.2024 - Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory BoardBOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), ... Seite 1
January 8, 2024
Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously...
November 21, 2023
MRT-2359 had acceptable tolerability with a favorable pharmacokinetic and pharmacodynamic profile in heavily pretreated patients with MYC-driven solid tumors, including lung cancer and high-grade neuroendocrine cancer.
October 17, 2023
Roche is paying $50 million up front to begin a drug R&D alliance with Monte Rosa Therapeutics, a biotech whose molecular glue technology could address targets previously deemed undruggable. It’s Roche’s second such deal in the past month.
July 26, 2023
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the
May 25, 2023
MRT-6160 has been selected for development by Monte Rosa Therapeutics for the treatment of multiple sclerosis and other autoimmune disorders.
May 23, 2023
23.05.2023 - Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression in autoimmunity models, supporting potential applications across multiple autoimmune diseasesPlanned IND filing in the first half ... Seite 1